Nearly half of patients who completed 56 weeks of treatment with Orexigen Therapeutics Inc’s experimental obesity treatment, Contrave, lost at least 10 percent of their weight in a late-stage study and the drug also appeared to help cholesterol and blood sugar levels. The drug demonstrated an even greater improvement in non- weight loss measures in patients [...]
Continue reading...Thursday, July 9, 2009
NEW YORK (Reuters) – Amylin Pharmaceuticals Inc said on Thursday a mid-stage study of its combination obesity product involving versions of hormones linked to appetite and metabolism yielded positive results. The Phase 2, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of the product, which contains the compounds pramlintide and [...]
Continue reading...
Saturday, October 24, 2009
0 Comments